ArticleBMC public health2026
The Covid-19 pandemic as an inflection point in US mortality trends from hematologic and circulatory system diseases: a piecewise trend analysis.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe COVID-19 pandemic disrupted healthcare systems and may have influenced mortality trends in hematologic-immune disorders (D50-D89) and Diseases of the circulatory system (I00-I99). This study evaluates US mortality trends from 2010 to 2023 to assess potential pandemic-related changes.
methodsWe utilized spline regression modeling on CDC WONDER mortality data (2010-2023) to quantify post-pandemic trend shifts in both age-adjusted and sex/age-stratified mortality rates.
resultPost-2019 mortality trends for D50-D89 and I00-I99 diseases showed significant increases, particularly among older adults and younger males. D50-D89 mortality in females ≥ 65 increased ~ 2.6% (95% CI 1.70% to 3.68%) annually, while males ≥ 65 increased ~ 1.6% (95% CI 0.28% to 3.07%) annually; younger males (15-34 years) showed a 4.5% (95% CI 0.49% to 8.87%) annual increase. I00-I99 mortality increases were most pronounced in older females (~ 1.4% annual increase, 95% CI 0.49 to 2.31). Analysis of standardized rates in all groups except for men in I00-I99 showed a positive slope-shift after 2019. (p < 0.05)".
conclusionThese findings highlight the persistent impact of the COVID-19 pandemic on hematologic and circulatory system disease mortality, emphasizing the need for continued monitoring of vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.